French drug major Sanofi-Aventis says that the US Food and Drug Administration has approved Apidra (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (four years and older) with diabetes mellitus.
The approval of the drug for pediatric use is based on the FDA's review of a 26-week, Phase III, open-label, active control study of Apidra in comparison with insulin lispro, in 572 children and adolescents (four years and older) with type 1 diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze